EGFR and neoplasm: Several large‐scale clinical studies have confirmed that the combination of traditional chemotherapy and bevacizumab or recombinant human endostatin can increase PFS and OS in patients with advanced NSCLC,11, 12, 13 In a few clinical trials, bevacizumab combined with EGFR‐TKI erlotinib has also been confirmed to enhance the effect of tumor inhibition.14